Organofluorides

Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities

Retrieved on: 
Monday, January 11, 2021
Dipraglurant, Imidazopyridines, Organofluorides, U.S. Securities and Exchange Commission, Underwriting, Chemistry

The aggregate gross proceeds from the offering are $11.5 million, before deducting the underwriting discounts and commissions and offering expenses payable by Addex.

Key Points: 
  • The aggregate gross proceeds from the offering are $11.5 million, before deducting the underwriting discounts and commissions and offering expenses payable by Addex.
  • These include dipraglurant, an mGlu5 negative allosteric modulator, for use in Parkinson's disease and dystonia, and its preclinical pipeline.
  • The New Shares are expected to begin trading on the SIX Swiss Exchange on January 12, 2021.
  • 333-251322), as amended, with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on January 6, 2021.

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

Retrieved on: 
Monday, January 11, 2021
Organofluorides

- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients.

Key Points: 
  • - ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients.
  • The approval was received following a review by the DMC of blinded safety data from all three dose cohorts of the MAD study.
  • ASLAN plans to immediately commence recruitment of at least 18 patients into the expansion cohort, with at least 12 patients dosed weekly with 600mg ASLAN004 and the rest receiving placebo.
  • The Phase 1 study is evaluating three doses of ASLAN004 (200mg, 400mg and 600mg) delivered subcutaneously and includes a fourth (expansion) cohort.

Insights on the Magnetic Refrigeration Global Market to 2025 - Featuring Ubiblue, Camfridge and BASF Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, January 8, 2021
Supply chain management, Retail, Home Goods, Heating, ventilation, and air conditioning, Physical sciences, Articles, Science and technology, Organofluorides, Food preservation, Home appliances, Thermodynamics, Hydrofluorocarbon, Refrigeration, Air conditioning, High-fructose corn syrup

The "Magnetic Refrigeration Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Magnetic Refrigeration Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The magnetic refrigeration market is estimated to grow at a CAGR of 50.44% to reach US$202.757 million in 2025 from US$17.493 million in 2019.
  • There has been a growing focus to reduce the global warming to below 2C by 2100.
  • 200 countries recently agreed on dramatically reducing the reliance on climate change causing chemicals called hydrofluorocarbons (HFCs) in air conditioning and refrigeration.

Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients

Retrieved on: 
Friday, January 8, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Chloroarenes, Organofluorides

The ICONA study (ICOsabutate in NASH) aims to randomise 264 patients to one of three different treatment groups: placebo, icosabutate 300 mg once daily, or icosabutate 600 mg once daily, with a treatment period of 52 weeks.

Key Points: 
  • The ICONA study (ICOsabutate in NASH) aims to randomise 264 patients to one of three different treatment groups: placebo, icosabutate 300 mg once daily, or icosabutate 600 mg once daily, with a treatment period of 52 weeks.
  • The interim analysis of secondary endpoints from the first 90 patients treated for 16 weeks has been completed and shows good efficacy and positive safety.
  • Gastroenterology 2019;156:88-95 e85
    Professor Stephen Harrison, Principal Investigator of the ICONA study, commented: NASH with fibrosis represents a huge area of unmet need.
  • A Phase 2b study was initiated in July 2019 (ICONA) to study the efficacy of icosabutate in NASH.

Dexamethasone Market - Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026: The Rise of Dexamethasone as a Lifesaving Treatment for Critically Ill COVID-19 Patients - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 7, 2021
Health, Pharmaceutical, COVID-19, COVID-19 drug development, Dexamethasone, Organofluorides, Otologicals, Pregnanes, Drugs, Chemistry, Organic compounds

The "Dexamethasone Market By Formulation type, By Application, and End user - Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dexamethasone Market By Formulation type, By Application, and End user - Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com's offering.
  • The report covers forecast and analysis for the Dexamethasone market on a global and regional level.
  • Additionally, the report includes the study of opportunities available in the Dexamethasone market on a global as well as regional level.
  • The report provides company market share analysis in order to give a broader overview of the key players in the Dexamethasone market.

World Dexamethasone Consumption Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 7, 2021
Health, Pharmaceutical, COVID-19, COVID-19 drug development, Dexamethasone, Organofluorides, Otologicals, Pregnanes, Drugs, Spreadsheet, Chemistry, Organic compounds

The "CAS Dexamethasone World Consumption Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CAS Dexamethasone World Consumption Report" report has been added to ResearchAndMarkets.com's offering.
  • This CAS Dexamethasone World Consumption Report provides data on the net consumption of CAS 50-02-2 - Dexamethasone Substance(s) in each of the countries listed.
  • The CAS Dexamethasone World Consumption Reports gives 6 pages of data for each of about 200 countries, plus thousands of database tables and spreadsheets.
  • This product provides users with commercial intelligence on Dexamethasone markets and industries about 200 countries.

Natural Refrigerants Highlighted as Key Climate Solution at TEDxReImagineScience Event

Retrieved on: 
Thursday, January 7, 2021
Other Natural Resources, Supermarket, Alternative energy, Energy, Food, Beverage, Natural Resources, Environment, Retail, Science, Chemicals, Plastics, Manufacturing, Other Science, Heating, ventilation, and air conditioning, Chemistry, Physical sciences, Industrial gases, Organofluorides, Refrigerants, Natural sciences, Natural refrigerant, Hydrofluorocarbon, Organofluorine chemistry, Fluorine, North American Sustainable Refrigeration Council, TEDx, x = independently organized event, TED

Nine months pregnant and speaking within days of her due date, Wright drove home a powerful message of hope and collective action on an important, but little-known climate solution natural refrigerants.

Key Points: 
  • Nine months pregnant and speaking within days of her due date, Wright drove home a powerful message of hope and collective action on an important, but little-known climate solution natural refrigerants.
  • Wright explained that traditional Hydrofluorocarbon (HFC) refrigerants are super-polluting greenhouse gases with thousands of times more impact on the climate than carbon dioxide.
  • Natural refrigerants give me hope because they have the power to make the number one global climate solution a reality, said Wright.
  • The bill is an important step towards making natural refrigerants a more feasible option for grocers and making this leading climate solution a reality.

Chemours is Prepared to Support US Industry with Pivotal Next Generation, Low Global Warming Potential Technologies

Retrieved on: 
Tuesday, January 5, 2021
Chemical compounds, Refrigerants, Chemistry, Physical sciences, Organofluorides, Greenhouse gases, Hydrofluoroolefin, Global warming potential, Chemours, HFO, Carbon dioxide, GWP

In support of the phase down, Chemours has developed and commercialized a portfolio of low global warming potential (GWP) solutions leveraging hydrofluoroolefin (HFO) technology.

Key Points: 
  • In support of the phase down, Chemours has developed and commercialized a portfolio of low global warming potential (GWP) solutions leveraging hydrofluoroolefin (HFO) technology.
  • "Chemours has been consistent in our support of orderly HFC phase down actions globally.
  • By the year 2025, Chemours estimates that its low GWP products will eliminate an estimated 325 million tons of carbon dioxide equivalents on a global basis.
  • Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy

Retrieved on: 
Monday, January 4, 2021
Health, Diabetes, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemical compounds, Clinical research, Design of experiments, Placebo-controlled study, Pyrimidines, Organofluorides, Health sciences, Health, Palifermin, COVID-19 drug repurposing research, the Phase 2 Painful DPN Study, Neuropathic Pain and Painful Diabetic Peripheral Neuropathy, NYX-2925, Aptinyx

Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the United States.

Key Points: 
  • Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the United States.
  • The Phase 2 study is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of NYX-2925 in patients with advanced painful DPN.
  • Approximately 200 patients will be enrolled in the study.
  • Following a screening period, eligible patients will be randomized to receive oral doses of NYX-2925 50 mg or placebo once daily over the treatment period.

Hudson Technologies Applauds Adoption of Omnibus/Covid-19 Relief Which Includes the Phasedown of HFC Production

Retrieved on: 
Tuesday, December 29, 2020
Organofluorides, Heating, ventilation, and air conditioning, Industrial gases, Refrigerant, Chemistry, Hydrofluorocarbon, Physical sciences, High-fructose corn syrup, Organofluorine chemistry, Chemical compounds

The law includes language in Section 103, Division S that would require the phasedown of virgin production of hydrofluorocarbons (HFCs), while increasing opportunities for reclamation of HFCs.

Key Points: 
  • The law includes language in Section 103, Division S that would require the phasedown of virgin production of hydrofluorocarbons (HFCs), while increasing opportunities for reclamation of HFCs.
  • Brian F. Coleman, President and Chief Executive Officer of Hudson Technologies commented, We are very pleased with the Omnibus/Covid-19 Relief package, which includes the phasedown of virgin production of HFC refrigerants.
  • Hudsons founder, Kevin J. Zugibe, PE, built our Company around his vision to promote sustainability and a circular economy in the refrigerant industry.
  • Our industry, along with many NGOs, has been working diligently to assist the Federal governments development of a program for the orderly phasedown of virgin HFC production and use.